RSS-Feed abonnieren
DOI: 10.1055/s-0038-1653824
Raised Plasma Fibrinogen Concentrations in Subjects Attending a Metabolic Ward - Relation to Family History and Vascular Risk Factors
Publikationsverlauf
Received 30. Mai 1994
Accepted after resubmission 05. Januar 1995
Publikationsdatum:
09. Juli 2018 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00035024/199504/lookinside/thumbnails/10-1055-s-0038-1653824-1.jpg)
Summary
We have evaluated plasma fibrinogen levels in 171 subjects attending a metabolic ward. As in the general population, a significant difference in plasma fibrinogen concentrations (p <0.05) was found between subjects with diabetes mellitus or hypertension and those without. However, fibrinogen was also abnormally high (p <0.05) when evaluated according to the presence of a family history of ischemic complications of atherosclerosis (p <0.05). In this setting, fibrinogen correlated with diabetes mellitus or hypertension as well as with familial risk, and the latter interacted with hypertension (p <0.05) in accounting for plasma fibrinogen.
The relationships between certain fibrinogen genotypes and familial risk have then been evaluated. Analysis of a locus (1.3 kb, HAE III digestion) of the promoter region of the BB fibrinogen gene, identified a polymorphic cutting site. The allele with the alternative restriction site (HI) was associated with mean fibrinogen levels which were 0.1-0.3 g/1 lower than those associated with the other allele (H2). This difference was not statistically significant. No obvious association was found between the familial risk and the presence of the H2 allele. We conclude that in a group of subjects from a metabolic ward, a positive family history for ischemic complications of atherosclerosis is consistently associated with high plasma fibrinogen levels. Interaction with hypertension significantly strengthens the association.
-
References
- 1 Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a metaanalysis and review of the literature. Ann Int Med 1993; 118: 956-963
- 2 Di MinnoG, Mancini M. Measuring plasma fibrinogen to predict stroke and myocardial infarction. Arteriosclerosis 1990; 10: 1-7
- 3 Hoffman CJ, Bums P, Lawson WE, Katz JP, Miller RH, Hultin MB. Plasma fibrinogen level is not elevated in young adults from families with premature ischemic heart disease. Arterioscl Thrombos 1993; 13: 800-803
- 4 Roncaglioni MC, Santoro L, D'Avanzo B, Negri E, Nobili A, Ledda A, Pietropaolo F, Franzosi MG, La VecchiaC, Feruglio GA, Maseri A. Role of family history inpatients with myocardial infarction: an italian case-control study. Circulation 1992; 85: 2065-2072
- 5 Bara L, Nicaud V, Tiret L, Cambien F, Samama MM. Expression of paternal history of premature myocardial infarction on fibrinogen, factor VIIC and PAI-1 in European Offspring. The EARS Study Thromb Haemost 1994; 71: 434-440
- 6 Hamsten A, de Faire U, Iselius L, Blomback M. Genetic and cultural inheritance of plasma fibrinogen concentration. Lancet 1987; 2: 988-990
- 7 Roy SN, Mukhopadhyay G, Redman CN. Regulation of fibrinogen assembly. Transfection of Hep G2 cells with Bb cDNA specifically enhances synthesis of the three component chains of fibrinogen. J Biol Chem 1990; 265: 6389-6393
- 8 Humphries SE, Cook M, Dubovitz M, Stirling Y, Meade TW. Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet 1987; 1: 1452-1455
- 9 Thomas AE, Green FR, Kelleher CH, Wilkes HC, Brennan PJ, Meade TW, Humphries SE. Variation in the promoter region of the beta fibrinogen gene is associated with plasma fibrinogen levels in smokers and nonsmokers. Thromb Haemost 1991; 65: 487-490
- 10 Fowke FG, Connor JM, Smith FB, Wood J, Donnan PT, Lowe JD O. Fibrinogen genotype and risk of peripheral atherosclerosis. Lancet 1992; 339: 693-696
- 11 Connor JM, Fowkes FG, Wood J, Smith FB, Donnan PT, Lowe GD O. Genetic variation at fibrinogen loci and plasma fibrinogen levels. J Med Genet 1992; 29: 480-482
- 12 Scarabin PY, Bara L, Ricard S, Poirier O, Cambou JP, Arveiler D, Luc J, Evans AE, Samama MM, Cambien F. Genetic variation at the β-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction. The ECTIM study Arterioscl Thrombos 1993; 13: 886-891
- 13 Green F, Hamsten A, Blomback M, Humphries S. The role of β-fibrinogen genotype in determining plasma fibrinogen levels in young survivors of myocardial infarction and healthy controls from Sweden. Thromb Haemost 1993; 70: 915-920
- 14 Di MinnoG, Mancini M. Drugs affecting plasma fibrinogen levels. Cardiovasc Drug Ther 1992; 6: 319-321
- 15 Guidelines Sub-Committee. 1993 Guidelines for the management of mild hypertension: Memorandum from a WHO/ISH Meeting. High Blood Press. 1993; 2: 169-186
- 16 National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979; 28: 1039-1057
- 17 Di MinnoG, Cerbone AM, Cirillo F. et al Hemostatic variables in homozygous familial hypercholesterolemia. Effect of regular plasma cholesterol removal by low density lipoprotein apheresis. Arteriosclosis 1990; 10: 1119-1126
- 18 Von ClaussA. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-246
- 19 Blin N, Stafford DW. A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Res 1976; 3: 2303
- 20 Saiki RH, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988; 239: 489-491
- 21 Maniatis T, Fritsch EF, Sambrook J. Molecular Cloning: a laboratory manual. 2nd Edition Cold Spring Harbor Laboratory. New York: Cold Spring Harbor; 1989
- 22 Norusis MJ. SPSS/PC +V2.0 Base manual. Chicago: III SPSS Inc. Publisher; 1988
- 23 Sing CF, Davignon J. Role of apoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet 1985; 37: 268-285
- 24 International Task Force for Prevention of Coronary Heart Disease. Prevention of coronary heart disease: Scientific background and new clinical guidelines. Recommendations of the European Atheorsclerosis Society Nutr Metab Cardiovasc Dis 1992: 2113-2156
- 25 Thompson SG, Martin JC, Meade TW. Sources of variability in coagulation factor assays. Thromb Haemost 1987; 58: 1073-1077
- 26 Berg K, Kierulf P. DNA polymorphisms at fibrinogen loci and plasma fibrinogen concentrations. Clin Genet 1989; 36: 229-235
- 27 Huber P, Laurent M, Dalmon J. Human b fibrinogen gene expression. Upstream sequences involved in its tissue specific expression and its dex- ametasone and interleukin 6 stimulation J Biol Chem 1990; 265: 5695-5701
- 28 Heinrich PC, Castell JV, Andus T. Interleukin 6 and the acute-phase response. Biochem J 1990; 265: 621-636
- 29 Munro JM, Cotran RS. The pathogenesis of atherosclerosis: atherogenesis and inflammation. Lab Invest 1988; 58: 249-261
- 30 Bini A, Kudryk B. Fibrin and its derivatives in the normal and diseased vessel wall. Ann NY Acad Sci 1992: 112-126